Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study

Peselow, Eric D., Clevenger, Steven, IsHak, Waguih W. · 2016 · International Clinical Psychopharmacology

Abstract

Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mood-stabilizing agents: lithium (Li), valproic acid (VPA), and carbamazepine (CBZ), in preventing relapse episodes. A total of 225 patients with bipolar disorder were included in the present analysis. Patients taking Li, VPA, or CBZ were followed up for up to 124 months, until suffering a manic, mixed, or depressive episode (relapse), or until the end of the study/study termination (no relapse), whichever came first. The median unadjusted survival time was 36 months for patients taking VPA, 42 months for patients taking CBZ, and 81 months for patients taking Li. These results indicate that patients stayed longer on Li, suggesting that it might have been better tolerated than either CBZ or VPA. χ-Analysis showed that patients taking Li were significantly less likely to experience relapse during the observational period than patients taking either VPA or CBZ (P<0.05). A Cox regression model showed that the hazard of experiencing relapse was significantly predicted by the total number of depressive (P=0.007) and manic symptoms (P=0.02) assessed before the observation period. In addition, after controlling for symptom covariates, the hazard of experiencing relapse was 1.66 times (95% confidence interval 1.03-2.67) or 66% higher for patients taking VPA compared with patients taking Li (P=0.037). Although the hazard of experiencing relapse was higher for patients taking CBZ compared with those taking Li, the risk was not elevated by a significant amount. Notwithstanding the limitations of the naturalistic design of this study, the differences in relapse prevention and survival time observed in these medications show Li fairing relatively better in prophylactic therapy.

Overview

Integrity signals

Registry

Crossref · 10.1097/yic.0000000000000097

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 3

  1. Culpepper, 2014, Prim Care Companion CNS Disord, 16, PCC.13r01609
  2. Lambert, 1966, Ann Med Psychol, 1, 707
  3. MacRitchie, 2001, Cochrane Database Syst Rev, 3, CD003196

Cited by

See all 36

Metadata

Authors
Peselow, E. D., Clevenger, S., & IsHak, W. W.
Affiliations
Cedars-Sinai Medical Center (US)
Corresponding author
IsHak, Waguih W.
Venue
International Clinical Psychopharmacology
Published
2016-07
Volume
31
Issue
4
Pages
218-223
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2153764535
Cited by
31
References
26
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 2
FWCI
2.70
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
bipolar disorder, mood stabilizers, lithium, valproic acid, carbamazepine, prophylaxis, relapse prevention, maintenance therapy, treatment tolerability, survival time
MeSH terms
Adult, Bipolar Disorder, Carbamazepine, Female, Follow-Up Studies, Humans, Lithium, Male, Middle Aged, Valproic Acid, Treatment Outcome, Antimanic Agents, Secondary Prevention, Post-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study. https://app.cochat.ai/papers/10.1097/yic.0000000000000097
The paper
Peselow, E. D., Clevenger, S., & IsHak, W. W. (2016). Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000097

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.